September 9, 2025 4:49pm

A wink, a blink and a nod to the short-term with binoculars needed for the near and long-term

The mouth covered whisper as “uncle algo and his electronic trading dwarfs” revisit the oversold and “re-fill the frig” of cell and gene therapy pops

Remember, “The sector is what it is, until it isn’t, even if it doesn’t seem to be, it yet will be.”  Never leave an investor uninformed!  

I answer or qualify the sector’s equity’s movement; with an emphasis on which company is gaining or losing stride in your portfolio for the short-term

 

Tuesday’s RegMed Investors’ (RMi) pre-open: Waiting the wait … https://www.regmedinvestors.com/articles/14097

RegMed Investors (RMi) Research Note: Harvard Apparatus GT (OTCQB): Just another wrinkle – Q2/25’s 10-Q – liabilities exceed cash position … https://www.regmedinvestors.com/articles/13812

 

Tuesday: The Dow closed UP +196.39 points or +0.43%, the S&P closed UP +17.46 points or +0.27% while the Nasdaq closed UP +80.79 points or +0.37%

  • Theme of the session, despite job “worries” look past concerns about the state of the U.S. economy

Henry’omics: We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy

  • Job growth revised down through March, signaling economy on shakier footing than realized. Annual revisions to nonfarm payrolls data for the year prior to 3/25 showed a drop of 911,000 from the initial estimate. The numbers, which are adjusted from data in the quarterly census and reflect updated information on business openings and closings, add to evidence that the employment picture is weakening.

Tuesday’s my 40-company covered sector’s advance/decline line opened negative with 16 incliners, 24 decliners and 0 flats ending with a positive close of 24 incliners, 15 decliners and 1 flat

Metrics:  Tuesday, the IBB was up +0.73%, the XBI was up +0.55% while the VIX was down -0.01 points or -0.07% at 15.10

 

Q3 – 1 holiday, 2 negative and 4 positive closes

  • August – 12 negative and 9 positive closes
  • July – 1 market holiday, 13 positive and 9 negative closes

 

Tuesday Closing UP (10 of 24) 

  • Alnylam Pharmaceuticals (ALNY +$27.10 after Monday’s +$3.03),
  • Ionis Pharmaceuticals (IONS +$3.42),
  • IQV Holdings (IQV +$1.99),
  • Vertex Pharmaceuticals (VRTX +$1.23 after Monday’s -$0.87),
  • Agenus (AGEN +$0.81),
  • Arrowhead Pharmaceuticals (ARWR +$0.56 after Monday’s -$1.91),
  • Mesoblast (MESO +$0.45 after Monday’s +$0.16),
  • Beam Therapeutics (BEAM +$0.42 after Monday’s -$0.94),
  • Regenxbio (RGNX +$0.41),
  • AxoGen (AXGN +$0.38 after Monday’s +$0.06),

Flat (1)

  • Harvard Apparatus RT (OTCQB: HRGN $0.00 after Monday’s +$0.17)

Tuesday’s Closing DOWN (10 of 15): 

  • Vericel (VCEL -$0.68 after Monday’s -$0.83),
  • BioNTech SE (BNTX -$0.57 after Monday’s -$9.80),
  • Moderna (MRNA -$0.41),
  • Voyager Therapeutics (VYGR -$0.36 after Monday’s +$0.02),
  • Entrada Therapeutics (TRADA -$0.14),
  • Solid Biosciences (SLDB -$0.13),
  • WVE Life Sciences (WVE -$0.10 after Monday’s -$0.71),
  • Adverum Biotechnologies (ADVM -$0.07 after Monday’s +$0.02),
  • MiMedx (MDXG -$0.05 after Monday’s +$0.03),
  • Rocket Therapeutics (RCKT -$0.05),

 

The BOTTOM LINE:  More of the … WHYs …

Reiterating from Monday, “The cell and gene therapy seems to be currently residing and possibly staying in a … catalyst vacuum with more downside drift potentially coming into the markets which is … flirting with all-time highs in a … seasonally weak period.”

  • Again, from Monday’s morning post, “In the week, Wednesday’s PPI and wholesale inventories and Fed Chair Powell’s press conference at 2:30 p.m., ET, Thursday's CPI (inflation data) initial jobless claims, the weekly update on mortgage rates will be closely watched. Friday’s consumer sentiment could offer uncertain mix of upcoming inflation pressures; followed by None on Friday – Thankfully.

… unless there’s some event out of left field with regard to tariffs and like looming inflation reports and job data misses

 

A back-slap to equities, “Treasury yields rose in the bond market…

  • The latest discouraging report on the job market further cemented expectations for cuts to interest rates by the Fed with traders expecting at its meeting next week.

 

September: understand the “flow” …

  • 9/9 - Tuesday closed positive with 24 positive, 15 negative and 1 flat
  • 9/8 – Monday closed negative with 10 positive, 28 negative and 2 flats
  • 9/5 - Friday closed positive with 35 positive, 5 negative and 0 flat
  • 9/4 – Thursday closed negative with 17 positive, 21 negative and 2 flats
  • 9/3 - Wednesday closed positive with 22 positive, 16 negative and 2 flats
  • 9/2 -Tuesday closed positive with 22 positive, 18 negative and 0 flat
  • 9/1 -Monday was a holiday

Welcome to my world of defining the “grey’ in our universe!

  • “I hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”
  • If I have learned one thing as a former research analyst in a venture and public fund, operating executive, x-FBI, x-military officer and an adjunct (MBA) business school professor now a journalist; my life and your portfolio are largely tied to knowledge of price movements and questioning pricing targets and more.
  • I was once told by a “very” prominent figure early in my career, “write it right, keep it tight without hype and never lose the stride to guide the reader” – they were pretty simple instructions to follow!

 

Why do I keep repeating, so investors can make the connection …

The top three (3) performing in the session:   

  • Tuesday: Alnylam Pharmaceuticals (ALNY), Ionis Pharmaceuticals (IONS) and IQV Holdings (IQV)
  • Monday: Alnylam Pharmaceuticals (ALNY), Prime Medicine (PRME) and Harvard Apparatus RT (OTCQB: HRGN)
  • Friday: BioNTech (BNTX), IQVIA Holdings (IQV) and Beam Therapeutics (BEAM)

The worst three (3) in the session: 

  • Tuesday: Vericel (VCEL), BioNTech (BNTX) and CRISPR Therapeutics (CRSP)
  • Monday: BioNTech (BNTX), Lenz Therapeutics (LENZ) and Arrowhead Pharmaceuticals (ARWR)
  • Friday: Alnylam Pharmaceuticals (ALNY), Vertex Pharmaceuticals (VRTX) and Precigen (PGEN)

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC):

The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.